Phase 2 Rare Disease Deal Benchmarks

Phase 2 rare disease licensing deals carry a median total deal value of $1.6B, with upfront payments ranging from $138M to $433M. At this stage, deal structures are balanced between upfront and milestone payments, reflecting the proof-of-concept inflection. The recommended split allocates 18% to upfront and 82% to milestones.

The rare disease landscape at the phase 2 stage is characterized by limited competitive intensity per indication but growing platform competition. Development milestones average $283M, regulatory milestones contribute $322M, and commercial milestones reach $682M. Gene therapies and oligonucleotide-based approaches are transforming treatment paradigms, with orphan designations enabling premium pricing and accelerated regulatory paths.